



Date of original recommendation: 22nd June 2010

Date Re-reviewed: 16th December 2014

Glucosamine sulfate (Glusartel®) for the treatment of osteoarthritis of the knee.

The New Therapies Subgroup discussed the above drug at its meeting on the 16th December 2014. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Glucosamine sulfate (Glusartel®) for the treatment of osteoarthritis of the knee.

The group does not recommend the use of Glucosamine Sulfate on the NHS.

Although Glusartel® showed modest benefits against placebo, the group felt that the increased cost compared to other agents was not justified.

According to set criteria, glucosamine sulphate was deemed to be a low priority for funding.

Review date: September 2019

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.